Breaking News Instant updates and real-time market news.

PFE

Pfizer

$35.19

0.25 (0.72%)

, MRK

Merck

$54.90

(0.00%)

08:39
02/15/18
02/15
08:39
02/15/18
08:39

Pfizer and Merck provide update on Phase 3 trial of avelumab in NSCLC

Merck (MRK), Darmstadt, Germany, and Pfizer (PFE) announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer whose disease progressed after treatment with a platinum-containing doublet therapy. While the trial did not meet its prespecified endpoint of improving overall survival in patients with programmed death ligand-1-positive tumors, the proportion of patients in the chemotherapy arm crossing over to immune checkpoint inhibitors outside the study was higher than previously reported in post-platinum immunotherapy clinical trials, and this may have confounded this trial outcome. However, improvements in OS versus the control arm were observed in the moderate-to-high PD-L1+ expression - 50% or greater, which represented approximately 40% of the study population - and high PD-L1+ expression population - PD-L1+ expression 80% or greater, which represented approximately 30% of the study population -. The safety profile for avelumab in this trial was consistent with that observed in the overall JAVELIN clinical development program; no new safety signals were identified.

PFE

Pfizer

$35.19

0.25 (0.72%)

MRK

Merck

$54.90

(0.00%)

  • 16

    Feb

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

PFE Pfizer
$35.19

0.25 (0.72%)

02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
MRK Merck
$54.90

(0.00%)

02/15/18
02/15/18
UPGRADE
Target $78

Overweight
Bristol-Myers upgraded on immuno-oncology growth prospects at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bristol-Myers (BMY) to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. After the analyst reviewed combo toxicity in select combo studies with similar dosing as Bristol's CM-227 and compared cross trial against Merck's (MRK) Keynote-021G trial that tested Keytruda + chemo, he concluded that discontinuation rates due to side effects appear roughly comparable and now thinks Opdivo + Yervoy toxicity in lung cancer is likely to be acceptable. Risinger raised his price target on Bristol-Myers shares to $78 from $63.
02/15/18
PIPR
02/15/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using the selloff yesterday in shares of Biogen (BIIB) as a buying opportunity. The stock pulled back after management disclosed at a conference plans to up-size the Phase 3 aducanumab program by 510 patients total. While "this is a bit unnerving," particularly on the heels of another Phase 3 Alzheimer's failure for Merck's (MRK) verubecestat, the study remains blinded and variability on the primary endpoint can stem from a host of reasons, not all of them bad, Raymond tells investors in a research note titled "Aducanumab P3 Upsizing Doesn't Tell Us Much." The analyst does not think yesterday's news says much about the chances for an interim analysis or about aducanumab's efficacy profile. He keeps an Overweight rating on Biogen with a $407 price target.
02/14/18
BMOC
02/14/18
NO CHANGE
Target $65
BMOC
Outperform
Merck price target lowered to $65 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Merck to $65 after the company discontinued its APECS study. The analyst sees this as "another setback that increases Merck's dependence on Keytruda" and contends that the company needs other meaningful drivers. Arfaei keeps his Outperform rating based on his confidence in Keytruda growth and Merck's Immuno-oncology execution.
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.

TODAY'S FREE FLY STORIES

CGC

Canopy Growth

$47.83

1.75 (3.80%)

11:05
03/20/19
03/20
11:05
03/20/19
11:05
Options
Canopy Growth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.51

-0.195 (-2.24%)

11:03
03/20/19
03/20
11:03
03/20/19
11:03
Hot Stocks
Ford to invest over $850M to expand EV production capacity at Michigan plant »

Ford announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CMTL

Comtech

$21.65

-0.33 (-1.50%)

11:01
03/20/19
03/20
11:01
03/20/19
11:01
Hot Stocks
Comtech receives $2.2M contract for Midia gas development project in Romania »

Comtech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

F

Ford

$8.50

-0.205 (-2.36%)

11:01
03/20/19
03/20
11:01
03/20/19
11:01
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford to invest more than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

T

AT&T

$30.47

-0.23 (-0.75%)

10:55
03/20/19
03/20
10:55
03/20/19
10:55
Conference/Events
Economic Club of Washington, D.C. to hold luncheon meeting »

Chairman & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

GOOG

Alphabet

$1,206.02

6.31 (0.53%)

, GOOGL

Alphabet Class A

$1,209.61

6.48 (0.54%)

10:53
03/20/19
03/20
10:53
03/20/19
10:53
Periodicals
Supreme Court orders new look at $8.5M Google settlement, Bloomberg says »

The U.S. Supreme Court…

GOOG

Alphabet

$1,206.02

6.31 (0.53%)

GOOGL

Alphabet Class A

$1,209.61

6.48 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

BFRA

Biofrontera

$11.88

(0.00%)

10:52
03/20/19
03/20
10:52
03/20/19
10:52
Hot Stocks
Biofrontera says Ameluz Phase 3 study met primary regulatory endpoint »

Biofrontera announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$56.86

-0.1 (-0.18%)

10:50
03/20/19
03/20
10:50
03/20/19
10:50
Options
Aggressive call buyers in Qualcomm »

Aggressive call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

CYTK

Cytokinetics

$9.80

1.24 (14.49%)

10:47
03/20/19
03/20
10:47
03/20/19
10:47
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIGR

UP Fintech

$0.00

(0.00%)

10:43
03/20/19
03/20
10:43
03/20/19
10:43
Syndicate
Breaking Syndicate news story on UP Fintech »

UP Fintech opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

MNST

Monster Beverage

$56.91

-0.96 (-1.66%)

, FDX

FedEx

$171.66

-9.84 (-5.42%)

10:42
03/20/19
03/20
10:42
03/20/19
10:42
On The Fly
Monster, FedEx, Teradata downgrades among today's top analyst calls »

Check out today's top…

MNST

Monster Beverage

$56.91

-0.96 (-1.66%)

FDX

FedEx

$171.66

-9.84 (-5.42%)

NVRO

Nevro

$60.20

15.44 (34.50%)

TDC

Teradata

$45.50

-2.83 (-5.86%)

LYFT

Lyft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 01

    Apr

  • 02

    Apr

  • 30

    Apr

  • 25

    Jun

  • 29

    Mar

NVRO

Nevro

$60.27

15.51 (34.65%)

10:40
03/20/19
03/20
10:40
03/20/19
10:40
On The Fly
Nevro jumps over 30% after appointing new 'turnaround CEO' »

Shares of Nevro (NVRO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

VNQ

Vanguard REIT Index Fund

$84.62

-0.46 (-0.54%)

10:40
03/20/19
03/20
10:40
03/20/19
10:40
Options
Size put spread in Vanguard Real Estate ETF rolls a defensive position »

Size put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:40
03/20/19
03/20
10:40
03/20/19
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

UBER

Uber

$0.00

(0.00%)

10:39
03/20/19
03/20
10:39
03/20/19
10:39
Hot Stocks
Uber Freight launching in Europe »

After launching in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIGR

UP Fintech

$0.00

(0.00%)

10:33
03/20/19
03/20
10:33
03/20/19
10:33
Syndicate
Breaking Syndicate news story on UP Fintech »

UP Fintech indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

10:32
03/20/19
03/20
10:32
03/20/19
10:32
General news
Crude inventories for week of March 15 »

Crude oil inventories…

CAG

Conagra Brands

$22.68

-0.13 (-0.57%)

10:30
03/20/19
03/20
10:30
03/20/19
10:30
Options
Impressive call buy in Conagra longer-term contracts ahead of earnings »

Impressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

10:28
03/20/19
03/20
10:28
03/20/19
10:28
Syndicate
Breaking Syndicate news story on UP Fintech »

UP Fintech indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

F

Ford

$8.52

-0.19 (-2.18%)

10:25
03/20/19
03/20
10:25
03/20/19
10:25
Options
Ford call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

10:25
03/20/19
03/20
10:25
03/20/19
10:25
General news
U.S. equities rolled over into the red »

U.S. equities rolled over…

10:25
03/20/19
03/20
10:25
03/20/19
10:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

AIG

AIG

$43.84

-0.04 (-0.09%)

10:22
03/20/19
03/20
10:22
03/20/19
10:22
Hot Stocks
VALIC rebrands to AIG Retirement Services »

VALIC will now be known…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

10:20
03/20/19
03/20
10:20
03/20/19
10:20
Syndicate
UP Fintech indicated to open at $8.60, IPO priced at $8.00 »

UP Fintech (TIGR) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

LYFT

Lyft

$0.00

(0.00%)

, UBER

Uber

$0.00

(0.00%)

10:18
03/20/19
03/20
10:18
03/20/19
10:18
On The Fly
Lyft receives first Buy rating ahead of IPO »

Ride-hailing firm Lyft…

LYFT

Lyft

$0.00

(0.00%)

UBER

Uber

$0.00

(0.00%)

PIN

Pinterest

$25.55

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.